Edgar Filing: GORDON CARL L - Form 4

GORDON Form 4	CARL L									
April 20, 20	011									
FOR	M 4		CUDITIES				MUGGION	OMB A	PPROVAL	
	UNITED	STATES SE	CURITIES Washington			GE CO	MMISSION	OMB Number:	3235-0287	
Check t if no lo subject Section Form 4 Form 5 obligati	to 16. or Filed pu	MENT OF CH	SECU on 16(a) of t	RITIES the Securitie	es Exc	Act of 1934,	Expires: Estimated a burden hou response	irs per		
may co		(a) of the Publ 30(h) of th	ne Investmen	U 1	•		935 or Section	L		
(Print or Type	e Responses)									
1. Name and GORDON	Address of Reporting	Sym	Issuer Name an ibol IARIN COR		-	Is	Relationship of l ssuer	Reporting Per	son(s) to	
(Last)	(First)					NNJ	(Check	all applicable	e)	
C/O ORBI	IMED ADVISOR THIRD AVENUI	Date of Earliest Transaction Month/Day/Year) 4/18/2011				_X_Director10% Owner Officer (give titleOther (specify below)below)				
	(Street)		Amendment, l d(Month/Day/Ye	-		А	. Individual or Joi pplicable Line) X_ Form filed by O _ Form filed by Mo	ne Reporting Pe	erson	
NEW YOI	RK,, NY 10017					P	erson	ore than one Re	porting	
(City)	(State)	(Zip)	Table I - Non	-Derivative Se	ecuriti	es Acqui	red, Disposed of,	or Beneficial	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, any (Month/Day/Yea	Code	4. Securities . onor Disposed c (Instr. 3, 4 an Amount	of (D)	red (A) Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Ordinary Shares (1)	04/18/2011		S	1,756,471 (4)	D	\$ 14.86 (6)	4,682,029	I	See Footnotes (2) (3) (10)	
Ordinary Shares (1)	04/18/2011		S	16,668 <u>(5)</u>	D	\$ 14.86 (6)	44,832	I	See Footnotes (2) (3) (11)	
Ordinary Shares (1)	04/18/2011		S	1,214,227 (4)	D	\$ 15.65 (7)	3,467,802	I	See Footnotes (2) (3) (10)	
Ordinary	04/18/2011		S	11,522 (5)	D	\$	33,310	Ι	See	

Edgar Filing: GORDON CARL L - Form 4

Shares (1)				15.65 (7)		Footnotes (2) (3) (11)
Ordinary Shares (1) 04/18/2011	S	1,102 (4)	D	\$ 16.26 3,466,700 (8)	I	See Footnotes (2) (3) (10)
Ordinary Shares (1) 04/18/2011	S	10 <u>(5)</u>	D	\$ 16.26 33,300 (8)	I	See Footnotes (2) (3) (11)
Ordinary Shares (1) 04/20/2011	S	792,400 (4)	D	\$ 15.79 2,674,300 (9)	I	See Footnotes (2) (3) (10)
Ordinary Shares (1) 04/20/2011	S	7,600 <u>(5)</u>	D	\$ 15.79 25,700	Ι	See Footnotes (2) (3) (11)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	of Derivative	Number Expiration Date of (Month/Day/Year) Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3,		7. Titl Amou Under Secur (Instr.	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Х

GORDON CARL L C/O ORBIMED ADVISORS LLC 767 THIRD AVENUE, 30TH FLOOR NEW YORK,, NY 10017

Signatures

/s/ Carl L. Gordon

Repor

04/20/2011

**Signature of	
eporting Person	

Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v). *
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The Ordinary Shares (the "Shares") may be represented by American Depositary Shares, each of which currently represents one (1)Ordinary Share.

The reporting person is affiliated with OrbiMed Private Investments III, LP ("OPI III") and OrbiMed Associates III, LP ("Associates"), which hold the Shares reported herein. OrbiMed Capital GP III LLC ("Capital") is the sole general partner of OPI III. OrbiMed Advisors

LLC ("Advisors"), a registered adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of Capital (2)and the sole general partner of Associates. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of, and holder of a controlling interest in, Advisors. OPI III and Associates have designated a representative, currently the reporting person, a member of Advisors, to serve on the Issuer's board of directors.

The reporting person does not have sole voting or investment power over the securities held by OPI III and Associates. However, the reporting person may be deemed to have beneficial ownership of these securities by virtue of his affiliation with Advisors. The reporting

- person disclaims beneficial ownership of the Shares reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of (3)1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that the reporting person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- These Shares are beneficially owned by OPI III. (4)
- (5) These Shares are beneficially owned by Associates.

The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from \$14.25 to \$15.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the

(6) Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from \$15.25 to \$16.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the

(7) Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from \$16.25 to \$16.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the

(8) Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from \$15.40 to \$16.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the

- (9) Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote.
- (10) The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by OPI III.
- (11) The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Associates.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.